Aravindhan Veerapandiyan

Associate Professor

UAMS

Also affiliated: University of Iowa (2019); Boston Children's Hospital (2024); National Institutes of Health (2024); Arkansas Children's Hospital (2018–2026); State University of New York (2018); Children's National (2024); University of Louisville (2020); University of Miami (2020); Duke University (2010–2015); SUNY Downstate Health Sciences University (2018); Vanderbilt University (2024); University of Arkansas Medical Center (2019–2025); University Hospital of Bern (2024); The Ohio State University Wexner Medical Center (2024); University of Rochester Medicine (2018–2020); Stony Brook School (2018); Stony Brook Medicine (2018); Duke Medical Center (2010–2015); MSN Laboratories (India) (2019); Rutgers New Jersey Medical School (2013–2018); Arkansas Children's Research Institute (2021); The Ohio State University (2024); University of Rochester (2018–2020); Indiana University (2024); Stony Brook University (2018)

Peds Pediatrics, College of Medicine

21 h-index 148 pubs 1,557 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group UAMS TRI Profile

OverviewAI-generated summary

Aravindhan Veerapandiyan's research focuses on genetic therapies and the management of rare neuromuscular and genetic disorders, particularly in pediatric populations. He has investigated gene replacement therapy for Duchenne muscular dystrophy, contributing to the EMBARK phase 3 randomized trial, and has also studied its application in spinal muscular atrophy (SMA) types 1 and other forms. His work includes examining the real-world clinical outcomes for patients with SMA receiving treatments like Nusinersen.

Veerapandiyan's research extends to understanding the genetic basis of disorders, as evidenced by his work identifying novel mutations in the AGL gene for Glycogen Storage Disease Type III. He has also contributed to understanding the broader implications of genetic syndromes, such as social skills and psychopathology in children with chromosome 22q11.2 deletion syndrome. During the COVID-19 pandemic, he addressed the care of patients with various muscular dystrophies and contributed to understanding the spectrum of COVID-19 in children.

With an h-index of 20 and over 137 publications, Veerapandiyan leads a research group at the University of Arkansas for Medical Sciences. His collaborations primarily involve colleagues within the university, including Akilandeswari Aravindhan, Praveen Kumar Ramani, Ruthwik Duvuru, and Murat Gökden.

Metrics

h-index: 21
Publications: 148
Citations: 1,557

Positions

Associate Professor publications 2018–2026

University of Arkansas for Medical Sciences Peds Pediatrics, College of Medicine Institutional directory
University of Arkansas for Medical Sciences publications 2018–2026

ORCID

Selected Publications

Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial (2026)

The Lancet DOI OpenAlex
Navigating sexual health, fertility, and adult wellness in individuals with Duchenne muscular dystrophy: Current standards of care and future directions (2026)

Journal of Neuromuscular Diseases DOI OpenAlex
Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up (2026)

Cardiology and Therapy DOI OpenAlex
Caregiver perception of cardiac disease and advanced cardiac therapies in Duchenne muscular dystrophy: A national survey (2026)

Progress in Pediatric Cardiology DOI OpenAlex
Pathologic Variability Associated With Phenotypic Differences in Siblings With <scp>ACTA1</scp> Myopathy (2026)

Muscle & Nerve DOI OpenAlex
Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study (2026)

The Lancet Neurology 2 citations DOI OpenAlex
Learnings from Patient Mortality after Delandistrogene Moxeparvovec Administration: A Report of Two Cases and Expert Committee Considerations for Future Mitigation and Management (2026)

Human Gene Therapy 2 citations DOI OpenAlex
Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial (2026)

Neurology and Therapy 3 citations DOI OpenAlex
Assessing Delays in Time to Diagnosis of Duchenne Muscular Dystrophy: A Survey of Current Primary Care Practices (2025)

Cureus DOI OpenAlex
Adrenal Suppression in Duchenne Muscular Dystrophy: Management Strategies Incorporating Novel Steroid Vamorolone (2025)

Journal of the Endocrine Society DOI OpenAlex
Caregiver Perception of Cardiac Disease and Advanced Cardiac Therapies in Duchenne Muscular Dystrophy: A National Survey (2025)

SSRN Electronic Journal DOI OpenAlex
Caregiver-reported Patient Experiences with Duchenne Muscular Dystrophy: Qualitative In-trial Interviews 1 Year After Delandistrogene Moxeparvovec in the Pivotal EMBARK Trial (2025)

Neurology and Therapy DOI OpenAlex
Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy (2025)

Neuromuscular Disorders 6 citations DOI OpenAlex
Gaps in the Assessment and Care of Neurodevelopmental and Psychiatric Conditions Associated With Dystrophinopathy (2024)

Muscle & Nerve 7 citations DOI OpenAlex
Taking ACTION to detect myocarditis related to recombinant gene transfer therapy for Duchenne Muscular Dystrophy; Consensus recommendations for cardiac surveillance (2024)

Journal of Neuromuscular Diseases 9 citations DOI OpenAlex